Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection

Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection From Chemical Tools to Clinical Medicines: Nonimmunosuppressive Cyclophilin Inhibitors Derived from the Cyclosporin and Sanglifehrin Scaffolds Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin A Cyclophilin inhibitors as antiviral agents SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection Sanglifehrins A, B, C and D, Novel Cyclophilin-binding Compounds Isolated from Streptomyces sp. A92-308110. I. Taxonomy, Fermentation, Isolation and Biological Activity. Sanglifehrins A, B, C and D, Novel Cyclophilin-binding Compounds Isolated from Streptomyces sp. A92-308110. I. Taxonomy, Fermentation, Isolation and Biological Activity. Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment